Navigation Links
Judge Reserves Judgment In Cancer Drug Case

A High Court judge has revealed that he will not give an immediate judgment with regard to Ann Marie Rogers, a breast cancer patient, concerning her case against the NHS refusing her the Herceptin drug treatment. //Justice Bean has revealed that the case is too important as it will have its impact on other breast cancer patients also, for an immediate judgment. There will be no case of undue delay either, according to him. The Herceptin drug reduces the possibility of the HER-2 form of cancer by 50%.

The Swindon Primary Care Trust (PCT) is reported to have refused the drug to Marie Rogers, and she has been compelled to borrow £5,000 to finance her treatment. She is reported to have come to a stage wherein she can no longer afford the treatment. The PCT is funding the treatment with the drug in early stage cancers only in exceptional cases, which is sought to be declared irrational, arbitrary, and unlawful by Ian Wise, who is representing Ms Rogers.

The annual cost of treating a patient with the Herceptin drug is £21,800. Ms Rogers stands a 57% chance of her ailment recurring after a period of 10 years, according to Ian Wise, and refusing to finance her treatment may result in fatal consequences, thus depriving her of her right to life.

The advocate for the PCT, Philip Havers contends that the drug is yet to be licensed for early stage breast cancer, nor has its safety and efficacy been certified by the National Institute for Clinical Excellence (NICE). The policy of the PCT is also in conformity with the guidance of the Health Secretary, according to him. The judge is seeking to decide if the exceptional circumstances criteria can be made use of in some early stage cancers. A judgment with regard to case is expected to be delivered in the second week of February 2006.
'"/>




Page: 1

Related medicine news :

1. Websites Are Judged In Less Than A Second
2. Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas
3. Judge bans veiled lawyers in courtrooms
4. Pigeon Feathers to Judge Pollution Levels
5. Marine Reserves Protect Coral Reefs
6. Hospital asked to Compensate Victim – Judgment by Delhi High Cour
7. Judgment In Favor Of Merck For Vioxx Drug
8. Life Or Death: Parents Await High Court Judgment
9. Italian Court Presides Over the Judgment of Incurably Ill Italian Man, Pleading Euthanasia
10. Fibroids unlikely to Turn Cancerous
11. Virus Level could Predict Cervical Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: